AstraZeneca France executive committee appointments, Digi Mart USA News: AstraZeneca has announced the appointments of Nicolas Soustiel as Vice President, Head of Oncology for AstraZeneca France, effective November 1, 2026, and Sébastien Faure as Corporate Affairs Director, effective October 26, 2026.
Nicolas Soustiel now leads the French Oncology and Hematology division of AstraZeneca, which covers six therapeutic areas: lung cancers, digestive cancers, breast cancers, genitourinary cancers, gynecological cancers, and hematology. He oversees the division’s strategy as well as its commercial and medical activities, in support of AstraZeneca’s oncology ambition to one day eliminate cancer as a cause of death.
In this role, he also joins the Oncology leadership team for the Europe and Canada region.
Soustiel has more than twenty years of experience in the healthcare sector in France and internationally, with in-depth expertise in oncology and hematology. Before this appointment, he was Senior Global Commercial Director at Johnson & Johnson Innovative Medicine, where he supervised the international commercial strategy for a multiple myeloma treatment and contributed to its global rollout.
Earlier, he was Director of the Oncology and Hematology Business Unit at Johnson & Johnson France. He also held leadership and strategy roles at major pharmaceutical companies including Pfizer and Takeda.
He holds a pharmacy doctorate from Université Paris-V, a Master’s in management from ESCP Business School, and completed an executive program at INSEAD.
Sébastien Faure has served as Corporate Affairs Director of AstraZeneca France since October 26, 2026. He is responsible for public affairs, communications, corporate social responsibility, and relations with patient associations.
He will play a key role in dialogue with stakeholders across the healthcare ecosystem, particularly on access to innovation and care, in what the company describes as a rapidly changing international and political context.
Faure has nearly twenty years of experience, mainly serving healthcare players. Before joining AstraZeneca, he worked at Nextep Health, a consulting firm specializing in public affairs and market access for health products, joining in 2008 and becoming a partner in 2020.
He also led Medvance, a consulting firm designing market access and public affairs strategies in European and international markets. He began his career at Edelman in Brussels, working on European institutional issues.
He is a graduate of Sciences Po Lille and holds a Master’s in European Business from ESCP Business School.
Auriane Cano-Chancel, President of AstraZeneca France, said: “I am delighted to welcome Nicolas and Sébastien to the AstraZeneca France Executive Committee. Their expertise, experience and commitment will help strengthen our work to improve access to innovative treatments and enhance patient care pathways.
I am confident they will mobilize our teams and all stakeholders in the ecosystem around these priorities for the benefit of patients.”
